Emactuzumab
Emactuzumab is an antibody pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against macrophage colony-stimulating factor 1 receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
7 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 2 | — | 1 | — | — | 3 |
| Giant cell tumors | D005870 | — | — | — | — | 1 | — | — | 1 |
| Giant cell tumor of tendon sheath | D000070779 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
| Carcinoma | D002277 | — | C80.0 | — | 1 | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
| Brenner tumor | D001948 | — | — | — | 1 | — | — | — | 1 |
| Endometrioid carcinoma | D018269 | — | — | — | 1 | — | — | — | 1 |
| Mucinous cystadenocarcinoma | D018282 | — | — | — | 1 | — | — | — | 1 |
| Mucinous adenocarcinoma | D002288 | — | — | — | 1 | — | — | — | 1 |
| Serous cystadenocarcinoma | D018284 | — | — | — | 1 | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | — | — | 1 | — | — | — | 1 |
| Transitional cell carcinoma | D002295 | — | — | — | 1 | — | — | — | 1 |
Show 5 more
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Emactuzumab |
| INN | emactuzumab |
| Description | Emactuzumab (RG-7155) is a humanized monoclonal antibody directed against colony stimulating factor 1 receptor (CSF-1R) expressed on macrophages and has demonstrated a profound antitumor effect through interference with the CSF-1/CSF-1R axis, along with a manageable safety profile in patients with diffuse-type tenosynovial giant cell tumors (d-TGCT).
... More |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL3545370 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB14905 |
| UNII ID | 6FY6EI1X8R (ChemIDplus, GSRS) |
Target
Agency Approved
CSF1R
CSF1R
Organism
Homo sapiens
Gene name
CSF1R
Gene synonyms
FMS
NCBI Gene ID
Protein name
macrophage colony-stimulating factor 1 receptor
Protein synonyms
CD115, CD115 antigen, CSF-1 receptor, CSF-1-R, CSF-1R, FMS proto-oncogene, M-CSF-R, macrophage colony stimulating factor I receptor, McDonough feline sarcoma viral (v-fms) oncogene homolog, Proto-oncogene c-Fms
...
More
Uniprot ID
Mouse ortholog
Csf1r (12978)
macrophage colony-stimulating factor 1 receptor (Q9DBH9)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 548 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
28 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use